--- title: "新的质量措施揭示了阿片类药物治疗项目中医疗补助患者保留率的显著差异" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273552099.md" description: "RTI International 在 JAMA Network Open 上发布的一项研究揭示了美国阿片类药物治疗项目（OTPs）中医疗补助患者保留率的显著差异。研究表明，仅有 61% 的医疗补助患者在第一个月后继续接受治疗，而排名最低的 25% 的项目仅保留了 40% 的患者。该研究强调了治疗保留作为阿片类药物使用障碍患者康复和生存的预测指标的重要性。研究结果建议，OTPs 可以利用这些基准来识别患者参与度改善的领域" datetime: "2026-01-23T20:10:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273552099.md) - [en](https://longbridge.com/en/news/273552099.md) - [zh-HK](https://longbridge.com/zh-HK/news/273552099.md) --- # 新的质量措施揭示了阿片类药物治疗项目中医疗补助患者保留率的显著差异 _RTI opioid treatment program-level measures of retention highlight opportunities for quality improvement_ RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 /PRNewswire/ -- A **new study** published in JAMA Network Open and authored by experts at RTI International, an independent scientific research institute, has found that many opioid treatment programs (OTPs) across the U.S. are struggling to keep patients engaged. According to the study, at typical opioid treatment programs, 61% of Medicaid patients remained in care beyond the first month, but, among the bottom quarter of programs, only 40% remained in treatment for at least one month. "For opioid use disorder, treatment retention is one of the strongest predictors of recovery and survival for patients experiencing opioid use disorder," said lead author **Tami Mark**, Ph.D., a Distinguished Fellow at RTI. "This new measure offers OTPs a consistent benchmark that shows how their retention rates align with national patterns, enabling programs to pinpoint strengths, isolate gaps and prioritize targeted improvements." RTI researchers created case-mix adjusted retention measures using Medicaid claims data from 2018 to 2023. In 2023, the measures included more than 1,100 OTPs, 432,000 treatment episodes, and 261,000 patients. The measures reveal a wide variation in OTPs' retention rates: - OTPs in the top 75% retained 73.5% of participants for 30 days, compared with 40.9% in the bottom 25%. - At 90 days, top OTPs retained 54.8%, while bottom–quartile programs retained 22.2%. - At 180 days, retention was 40.5% in the top group and 11.4% in the bottom group. RTI researchers **Dylan DeLisle**, MPH, Chelsea Katz, Ph.D.; **William Dowd**, Ph.D.; **Daniel Barch**, Ph.D.; Marianne Kluckman, MPH, also contributed to the study, which was supported by the **NIH HEAL Initiative**. **Read the full study** **Learn more about RTI's substance use research** **About RTI International** RTI International is an independent scientific research institute dedicated to improving the human condition. Our vision is to address the world's most critical problems with technical and science-based solutions in pursuit of a better future. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across social, statistical, data, and laboratory sciences, engineering, and other technical disciplines to solve the world's most challenging problems. For more information, visit **www.rti.org**. Media Contact: RTI International Media Relations 408153@email4pr.com 919-541-7300 View original content:https://www.prnewswire.com/news-releases/new-quality-measures-reveal-wide-variation-in-opioid-treatment-programs-medicaid-patient-retention-rates-302669211.html SOURCE RTI International ### 相关股票 - [CURE.US](https://longbridge.com/zh-CN/quote/CURE.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) - [IOVA.US](https://longbridge.com/zh-CN/quote/IOVA.US.md) - [RSPH.US](https://longbridge.com/zh-CN/quote/RSPH.US.md) - [ALKS.US](https://longbridge.com/zh-CN/quote/ALKS.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [ELV.US](https://longbridge.com/zh-CN/quote/ELV.US.md) - [MOH.US](https://longbridge.com/zh-CN/quote/MOH.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [PAHC.US](https://longbridge.com/zh-CN/quote/PAHC.US.md) - [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [CNC.US](https://longbridge.com/zh-CN/quote/CNC.US.md) - [HOOK.US](https://longbridge.com/zh-CN/quote/HOOK.US.md) - [RXL.US](https://longbridge.com/zh-CN/quote/RXL.US.md) - [UNH.US](https://longbridge.com/zh-CN/quote/UNH.US.md) - [ACHC.US](https://longbridge.com/zh-CN/quote/ACHC.US.md) - [CVS.US](https://longbridge.com/zh-CN/quote/CVS.US.md) - [UNHG.US](https://longbridge.com/zh-CN/quote/UNHG.US.md) - [XHS.US](https://longbridge.com/zh-CN/quote/XHS.US.md) - [IHF.US](https://longbridge.com/zh-CN/quote/IHF.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [INDV.US](https://longbridge.com/zh-CN/quote/INDV.US.md) ## 相关资讯与研究 - [FDA 将考虑扩大肽类复配范围](https://longbridge.com/zh-CN/news/283001654.md) - [Anthem Blue Cross 和 Blue Shield 与西奈山健康系统达成新的多年协议](https://longbridge.com/zh-CN/news/282626767.md) - [东方证券：全球首个 pan-RAS 药物数据惊艳 突破胰腺癌治疗困局](https://longbridge.com/zh-CN/news/282928576.md) - [OpenAI 推出药物研发 AI 模型 挑战谷歌](https://longbridge.com/zh-CN/news/283053858.md) - [募资 6.25 亿美元创五年之最 减肥药新贵 Kailera Therapeutics 今晚登陆纳斯达克](https://longbridge.com/zh-CN/news/283085982.md)